A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma

NCT00476554 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped slow accrual and financial resource limitation

Conditions

Cutaneous T-cell Lymphoma (CTCL)

Interventions

DRUG: Sapacitabine

Sponsor

Cyclacel Pharmaceuticals, Inc.